-+ 0.00%
-+ 0.00%
-+ 0.00%

HEALTH CANADA APPROVES KEYTRUDA® FOR THE TREATMENT OF ADULT PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER WHO ARE INELIGIBLE FOR CISPLATIN CONTAINING CHEMOTHERAPY, IN COMBINATION WITH ENFORTUMAB VEDOTIN, AS NEOADJUVANT TREATMENT AND THEN CONTINUED AFTER RADICAL CYSTECTOMY AS ADJUVANT TREATMENT

Reuters·08/05/2026 15:00:07

Please log in to view news